A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Castration-Resistant Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen (A6181120).
Phase of Trial: Phase III
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Prednisone (Primary) ; Sunitinib (Primary)
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 09 Dec 2013 Results published in the Journal of Clinical Oncology.
- 01 Dec 2011 Primary endpoint 'Overall-survival-duration' has not been met.
- 07 Jun 2011 Results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History